Clinical Overview
Dextromethorphan-Quinidine is a unique combination medication specifically indicated for the treatment of pseudobulbar affect (PBA), a neurological condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. This represents the first and only FDA-approved treatment specifically for PBA.
Primary Clinical Applications
Nuedexta is indicated exclusively for pseudobulbar affect associated with various neurological conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis, traumatic brain injury, stroke, and Alzheimer’s disease. It significantly reduces the frequency and severity of PBA episodes.
Mechanism and Clinical Benefits
Dextromethorphan acts as an NMDA receptor antagonist and sigma-1 receptor agonist, modulating emotional expression pathways. Quinidine serves as a CYP2D6 inhibitor, preventing dextromethorphan metabolism and maintaining therapeutic levels. This combination effectively reduces PBA episodes by 85% compared to placebo.
Unique Treatment Approach
This medication addresses a previously untreatable condition that significantly impacts quality of life for patients with neurological disorders. The combination allows for therapeutic dextromethorphan levels that would not be achievable with dextromethorphan alone due to rapid metabolism.
Prescribing Information
Dosing & Administration
Pseudobulbar Affect:
- Days 1-7: 1 capsule (20 mg dextromethorphan/10 mg quinidine) once daily
- Day 8 and beyond: 1 capsule twice daily (morning and evening)
- Maintenance: 2 capsules daily (40 mg dextromethorphan/20 mg quinidine total)
Administration:
- Take with or without food
- Swallow capsules whole, do not crush or chew
- Take approximately 12 hours apart when on twice-daily dosing
Missed Dose:
- Take as soon as remembered unless close to next dose
- Do not double dose
Indications
- Treatment of pseudobulbar affect (PBA)
- Associated with neurological conditions: ALS, MS, TBI, stroke, Alzheimer’s
Contraindications
- Hypersensitivity to dextromethorphan, quinidine, quinine, or mefloquine
- Complete AV block, second- or third-degree AV block (without pacemaker)
- History of quinidine-, quinine-, or mefloquine-associated thrombocytopenia
- MAOI use within 14 days
Warnings & Precautions
- Thrombocytopenia: Monitor platelet counts
- Hepatotoxicity: Monitor liver function
- Cardiac arrhythmias: QT prolongation, monitor ECG
- Hypersensitivity reactions: Including cinchonism
- Serotonin syndrome: Risk with serotonergic drugs
- Dizziness and falls: Particularly in elderly
Drug Interactions
- MAOIs: Contraindicated – risk of serotonin syndrome
- CYP2D6 substrates: Quinidine inhibits CYP2D6
- Digoxin: Increased digoxin levels
- Warfarin: Monitor INR
- Serotonergic drugs: Increased serotonin syndrome risk
Adverse Reactions
Common (≥3%):
- Diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema
Serious:
- Thrombocytopenia, hepatotoxicity, cardiac arrhythmias
Special Populations
- Renal Impairment: Use with caution in severe impairment
- Hepatic Impairment: Not recommended in moderate-severe impairment
- Pregnancy: Category C – use only if benefits outweigh risks
- CYP2D6 poor metabolizers: Increased dextromethorphan exposure
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
